# Calcinosis cutis in a patient with severe COVID-19 infection

- Amna Zahid<sup>1\*</sup>, Lucy Smith<sup>1</sup>, Arsalan Sheikh<sup>1</sup>,
- Naveen Sharma<sup>2</sup>, Maria Konstantopoulou<sup>1</sup>

### **European Journal of Medical Case Reports**

Volume 7(3):01-03 https://doi.org/10.24911/ejmcr/173-1659891215





This is an open access article distributed in accordance with the Creative Commons Attribution (CC BY 4.0) license: https://creativecommons.org/licenses/by/4.0/) which permits any use, Share — copy and redistribute the material in any medium or format, Adapt — remix, transform, and build upon the material for any purpose, as long as the authors and the original source are properly cited. © The Author(s) 2023

#### **ABSTRACT**

5

6

8

10

11 12

13

14

15

16

17

19

20

21

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

Background: Atypical presentation of calcinosis cutis in the context of COVID-19 infection complicated by acute renal failure has not been described in literature. We report a case of severe COVID-19 infection and its associated uncommon skin manifestation. It is a rare condition and its association with different diseases has been established in the past. However, to the authors' knowledge, calcinosis cutis has not yet been described in relation to COVID-19 infection complicated by acute renal failure.

Case Presentation: Here we describe a case of a 55-year-old gentleman admitted to the intensive care unit with severe COVID-19 infection whose hospital stay was complicated by acute renal failure and development of hypocalcemia which was treated with oral and intravenous calcium. Subsequently, he developed an atypical fleshy lesion on his left ankle during his in-patient stay which was histologically proven calcinosis cutis. It was successfully treated with topical medications.

Conclusion: This case highlights the importance of considering a wide differential of skin lesions including calcinosis cutis in patients who are critically unwell with COVID-19 or any other severe infections and develop isolated skin lesions in the setting of impaired renal functions and abnormal calcium phosphate metabolism with calcium administration.

Keywords: Calcinosis cutis, severe, COVID-19, SARS-COV-2: acute renal failure.

Received: 07 August 2022 Accepted: 25 January 2023 Type of Article: CASE REPORT Specialty: Dermatology

Correspondence to: Amna Zahid

\*Southport and Ormskirk NHS Hospitals Trust, Ormskirk Hospital, Ormskirk, UK. Email: amnakashif2007@hotmail.co.uk

Full list of author information is available at the end of the article.

### **Background**

Calcinosis cutis, a rare disease first described in 1985, implies pathological deposition of calcium in the skin and subcutaneous tissue. The exact pathological mechanism pertaining to disease presentation remains unclear however local inflammation may have a role in the development of the disease process. Its presentation has been linked to various diseases; however, it has not been demonstrated as a severe COVID-19 infection-related manifestation.

Our case denotes the combination of metastatic and iatrogenic calcification where severe COVID-19 infection resulted in acute renal failure and hypocalcemia requiring calcium administration and consequently the development of calcinosis cutis. Clinically, it commonly manifests as a firm to hard, whitish, or yellowish isolated or multiple lesions. However, in the case described below it was an uncommon, atypical fleshy appearance initially that was not diagnostic of calcinosis cutis and hence was not included in our list of differentials diagnosis until histologically proven.

# **Case Presentation**

- A 55-year-old gentleman with a known history of asthma 40
- and chronic migraine was admitted to the intensive care

unit (ICU) for invasive ventilation with severe COVID-19 infection. Regular medications included amitriptyline and inhalers. His ICU stay was complicated by acute renal failure requiring hemodialysis, staphylococcal bacteremia, and spontaneous splenic rupture. He was treated with dexamethasone, linezolid, and erythromycin. During the course of his illness, he developed hypocalcemia of 2.08 mmol/l (normal range: 2.2-2.6 mmol/l). Both oral calcium and intravenous calcium gluconate were administered to replace calcium deficiency for approximately 2 weeks. Four weeks later, he developed a tender lesion on the medial left ankle. It was fleshy in appearance initially; therefore, calcinosis cutis was the unlikely differential due to examination findings. It later developed into a 5-cm well-circumscribed yellowish indurated plaque with areas of ulceration and a few satellite lesions were also present (Figure 1).

45

47

49

50

52

53

55

56

57

58

59

61

63

The lesion was not entirely diagnostic, and the list of differential diagnoses included hypertrophic lichen planus, fungal infection, and impetigo. Metabolic screening demonstrated an elevated adjusted serum calcium of 2.97 mmol/l and phosphate of 1.86 mmol/l. Alkaline phosphatase was mildly elevated at 164 U/l (normal range: 30-130 U/l) with reactive hypoparathyroidism of



Figure 1. A well-circumscribed yellowish indurated plaque on the left medial ankle with ulceration.


0.9 mmol/l (normal range 1.6-6.9 mmol/l). Serum creatinine was significantly elevated at 540 umol/l initially but reduced to 269 umol/l following the hemodialysis, suggestive of acute renal failure. Serum inflammatory markers were moderately elevated with C-reactive protein (CRP) 50 mmol/l and WCC  $12.3 \times 10^{12}$ /l. Serum pH was normal, 7.39. The auto-immune profile for connective tissue disease screening was negative. A Computer tomography (CT) chest demonstrated COVID pneumonitis.

A punch biopsy of the skin lesion was performed to clarify an uncertain diagnosis. The histopathology at 10× magnification showed surface parakeratosis with dense calcification within the superficial dermis and calcification around blood vessels, consistent with calcinosis cutis (Figure 2).

The lesion was treated with a topical super-potent corticosteroid that resulted in significant improvement.

### Discussion

Our case demonstrates the novel aspect of skin manifestation in a COVID case [1]. Although, calcinosis cutis has been described in chronic renal failure [2,3], however, the appearance of atypical isolated skin lesions of uncertain significance and subsequently diagnosed as calcinosis cutis in the context of COVID and COVID-related acute renal failure has not been described previously. Calcinosis cutis is the abnormal deposition of calcium salts in the skin and subcutaneous tissue. There are four main etiologies: dystrophic, metastatic, iatrogenic, and idiopathic [4,5]. Dystrophic calcinosis cutis is the commonest type where tissue damage causes a release of phosphate protein which calcifies into subcutaneous tissue [6]. Calcium and phosphate levels are typically normal. The metastatic variant is associated with the abnormal metabolism of calcium and phosphate. Iatrogenic calcinosis cutis can occur by treatment with calcium salts [7], finally, the idiopathic variant occurs in the absence of any known tissue injury or



**Figure 2.** Surface parakeratosis with calcification in the superficial dermis and around blood vessels (original magnification ×10).

a systemic metabolic defect. The clinical presentation varies from solitary or multiple white-yellow firm papules, nodules, or plaques. Ulceration within a lesion results in pain. Occasionally, a chalky white discharge can be seen on the surface of the lesions. A diagnostic skin biopsy demonstrates abnormal calcium deposits in the specimen with stain dark blue with hematoxylin and eosin and black with Von Kossa stain [8].

Treatment is focused on the underlying cause. Topical sodium thiosulphate is utilized to increase the solubility of calcium [9]. Oral diltiazem, intralesional and topical corticosteroids, probenecid, bisphosphonates, and surgical excision have also been described to varying levels of success. Carbon dioxide laser has also been proven effective in treating some lesions [10].

This case demonstrates a combination of metastatic and iatrogenic calcinosis cutis [11,12]. Severe COVID-19 infection progressing to acute renal insufficiency and causing abnormal calcium metabolism is the most likely explanation of metastatic calcification in this case which was further complicated by administering calcium during his admission. This case corroborates that calcinosis cutis can be a differential diagnosis, especially in a patient with acute renal failure with the recent administration of calcium salts. It further highlights the importance of cautious administration of calcium in patients with severe COVID-19 disease and related renal impairment.

## **Conclusion**

This interesting case describes a presentation of calcinosis cutis in a patient with severe COVID-19 infection in the background of acute renal failure and calcium replacement. The development of organ failure carries the worst prognosis and denotes severe COVID-19 infection. Various cutaneous manifestations of COVID-19 have become known. However, this is a manifestation of an atypical clinical presentation of calcinosis cutis in

138	the context of severe SARS-COV-2 infection that has		
139	not been reported previously. Once diagnosed, calcinosis		
140	cutis should be managed according to the underlying eti-		
141	ologies which include dystrophic, metastatic, idiopathic,		
1/12	and introgenic		

#### What is new?

216

217

218

219

220

221

222

223

224

225

143

This interesting case describes a presentation of calcinosis cutis in a patient with severe COVID-19 infection in the background of acute renal failure and calcium replacement. The development of organ failure carries the worst prognosis and denotes severe COVID-19 infection. Various cutaneous manifestations of COVID-19 have become known. However, this is a manifestation of an atypical clinical presentation of calcinosis cutis in the context of severe SARS-COV-2 infection that has not been reported previously.

### **List of Abbreviations**

144 CRP C-reactive protein CT 145 Computer tomography ICU 146 Intensive care unit 147 WRC White cell count

#### **Conflict of interest** 148

- The authors declare that they have no conflicts of interest 149
- regarding the publication of this case report. 150

#### **Funding** 151

None. 152

#### 153 **Consent for publication**

- Written and informed consent was taken from the patient to 154
- 155 publish this case report.

#### 156 **Ethical Approval**

- 157 Ethical approval is not required at our institution to publish an
- 158 anonymous case report.

#### 159 **Author details**

- 160 Amna Zahid<sup>1</sup>, Lucy Smith<sup>1</sup>, Arsalan Sheikh<sup>1</sup>, Naveen Sharma<sup>2</sup>,
- 161 Maria Konstantopoulou<sup>1</sup>
- 1. Southport and Ormskirk NHS Hospitals Trust, Ormskirk 162 Hospital, Ormskirk, UK 163
- 2. St. Helens and Knowsley Teaching NHS Hospitals Trust, 164
- 165 Prescot, UK

#### References

- Singh H, Kaur H, Singh K, Sen CK. Cutaneous manifestations of COVID-19: a systematic review. Adv Wound Care (New Rochelle). 2021;10(2):51-80. https://doi. org/10.1089/wound.2020.1309
- Yip SL, Koo SC, Yen CH, Mak KH. Calcinosis cutis of the hand in a renal failure patient: a case report. J Orthop Surg (Hong Kong). 2011;19(1):113–5. https://doi. org/10.1177/230949901101900126
- Specchio F, Carboni I, Chimenti S, Tamburi F, Nistico' S. Cutaneous manifestations in patients with chronic renal failure on hemodialysis. Int J Immunopathol Pharmacol. 2014;27(1):1–4. https://doi. org/10.1177/039463201402700101
- Le C, Bedocs PM. Calcinosis cutis. Treasure Island, FL: StatPearls Publishing; 2022.
- Carrascosa MF, Pascual Velasco F, Corrales Martínez A, Fernández-Ayala Novo M, Casuso Sáenz E, Salcines Caviedes JR. Calcinosis cutis. BMJ Case Rep. 2011;2011:bcr0120113732. https://doi.org/10.1136/ bcr.01.2011.3732
- Larralde M, Giachetti A, Cáceres MR, Rodríguez M, Casas J. Calcinosis cutis following trauma. Pediatr Dermatol. 2005;22(3):227–9. https://doi. org/10.1111/j.1525-1470.2005.22309.x
- Moss J, Syrengelas A, Antaya R, Lazova R. Calcinosis cutis: a complication of intravenous administration of calcium glucanate. J Cutan Pathol. 2006;33(Suppl 2):60–2. https:// doi.org/10.1111/j.1600-0560.2006.00519.x
- Róbert L, Kiss N, Medvecz M, Kuroli E, Sárdy M, Hidvégi B. Epidemiology and treatment of calcinosis cutis: 13 years of experience. Indian J Dermatol. 2020;65(2):105-11. https://doi.org/10.4103/ijd.IJD 527 18
- García-García E, López-López R, Álvarez-Del-Vayo C, Bernabeu-Wittel J. latrogenic calcinosis cutis successfully treated with topical sodium thiosulfate. Pediatr Dermatol. 2017;34(3):356-8. https://doi.org/10.1111/pde.13116
- Kutlubay Z, Yardimci G, Gokler G, Engin B. A dystrophic calcinosis cutis case treated with CO<sub>2</sub> laser. J Cosmet Laser Ther. 2014;16(3):144-6. https://doi.org/10.3109/147641 72.2013.854622
- 11. Nigwekar SU, Kroshinsky D, Nazarian RM, Goverman J, Malhotra R, Jackson VA, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66(1):133-46. https://doi.org/10.1053/j. ajkd.2015.01.034
- 12. Millard TP, Harris AJ, MacDonald DM. Calcinosis cutis following intravenous infusion of calcium gluconate. Br J Dermatol. 1999;140(1):184–6. https://doi. org/10.1046/j.1365-2133.1999.02641.x

### Summary of the case

1	Patient (gender, age)	Male/55 years	
2	Final diagnosis	Calcinosis cutis	
3	Symptoms	Fleshy lesion left ankle	
4	Medications	Topical steroid	
5	Clinical procedure	Punch biopsy	
6	Specialty	Dermatology	

171 172

173 174

166

167

168

169

170

175 176

177 178 179

180

181

182 183 184

185 186

191 192 193

194 195 196 197

198 199 200 201

> 203 204 205

2.02

206

> 211 212 213

2.14 215

226

232